Dyne Therapeutics Inc. Insider Trading

DYN

⊜ Compare

Last 12 months

Insiders bought 315K and sold $169M on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−$168M

8 buys · 38 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

1 / 6

executives and directors

Last open-market buy

Oct 2026

Oct 2, 2026

Get an email when DYN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 2	Brian S Posner Director	Bought	2,500	$16.00	40K	10%	Form 4
Sep 4 – 8	Johanna Friedl-Naderer Chief Commercial Officer	Sold10b5-1 plan 2 parts	1,085	$23.42 average	25K	0.7%	Form 4
Sep 4 – 8	Douglas Kerr Chief Medical Officer	Sold10b5-1 plan 2 parts	5,035	$22.95 average	116K	3.0%	Form 4
Sep 8	John Cox CEO & President	Sold10b5-1 plan	5,658	$18.88	107K	1.3%	Form 4
Aug 13 – 14	Jason P Rhodes Director	Sold10b5-1 plan 6 parts	2,586,928	$25.20 average	$65.2M	86%	Form 4
Aug 13	Johanna Friedl-Naderer Chief Commercial Officer	Sold10b5-1 plan	226	$26.28	6K	0.1%	Form 4
Aug 13	Douglas Kerr Chief Medical Officer	Sold10b5-1 plan	1,556	$26.28	41K	0.9%	Form 4
Aug 13	Erick Lucera Chief Financial Officer	Sold10b5-1 plan	1,797	$26.28	47K	1.5%	Form 4
Aug 13	John Cox CEO & President	Sold10b5-1 plan	4,986	$26.28	131K	1.1%	Form 4
Jul 27	Dirk Kersten Director	Sold10b5-1 plan 2 parts	261,460	$25.51 average	$6.67M	6.8%	Form 4
Jul 6 – 7	Jason P Rhodes Director	Sold10b5-1 plan 10 parts	777,451	$22.97 average	$17.9M	100%	Form 4
Jun 26 – 29	Jason P Rhodes Director	Sold10b5-1 plan 6 parts	504,695	$21.23 average	$10.7M	34%	Form 4
Jun 23 – 25	Jason P Rhodes Director	Sold10b5-1 plan 9 parts	267,760	$21.09 average	$5.65M	20%	Form 4
Jun 25	Erick Lucera Chief Financial Officer	SoldNo plan	2,362	$20.37	48K	1.9%	Form 4
Jun 22 – 23	Dirk Kersten Director	Sold10b5-1 plan 3 parts	263,962	$20.70 average	$5.46M	6.4%	Form 4
Jun 17 – 18	Dirk Kersten Director	Sold10b5-1 plan 2 parts	84,355	$20.10 average	$1.7M	2.0%	Form 4
Jun 16	Johanna Friedl-Naderer Chief Commercial Officer	Sold10b5-1 plan	145	$18.33	3K	<0.1%	Form 4
Jun 16	Douglas Kerr Chief Medical Officer	Sold10b5-1 plan	887	$18.33	16K	0.5%	Form 4
Jun 16	John Cox CEO & President	Sold10b5-1 plan	2,683	$18.33	49K	0.6%	Form 4
Jun 8	Brian S Posner Director	Bought	2,000	$16.94	34K	8.9%	Form 4
Jun 3	Brian S Posner Director	Bought	2,500	$17.48	44K	13%	Form 4
May 26	Brian S Posner Director	Bought	2,000	$18.21	36K	11%	Form 4
May 20	Brian S Posner Director	Bought	2,500	$17.12	43K	16%	Form 4
May 13	Johanna Friedl-Naderer Chief Commercial Officer	Sold10b5-1 plan	228	$18.36	4K	0.1%	Form 4
May 13	Douglas Kerr Chief Medical Officer	Sold10b5-1 plan	1,564	$18.36	29K	0.9%	Form 4
May 13	Erick Lucera Chief Financial Officer	Sold10b5-1 plan	1,448	$18.36	27K	1.2%	Form 4
May 13	John Cox CEO & President	Sold10b5-1 plan	3,311	$18.36	61K	0.7%	Form 4
May 4 – 6	Jason P Rhodes Director	Sold10b5-1 plan 12 parts	106,723	$18.14 average	$1.94M	8.6%	Form 4
Apr 28	Jason P Rhodes Director	Sold10b5-1 plan 8 parts	227,337	$18.38 average	$4.18M	16%	Form 4
Apr 23 – 27	Jason P Rhodes Director	Sold10b5-1 plan 12 parts	384,549	$18.47 average	$7.1M	24%	Form 4
Apr 21 – 22	Dirk Kersten Director	Sold10b5-1 plan 2 parts	10,952	$20.01 average	219K	0.3%	Form 4
Apr 20 – 22	Jason P Rhodes Director	Sold10b5-1 plan 16 parts	834,302	$19.75 average	$16.5M	39%	Form 4
Apr 17 – 20	Dirk Kersten Director	Sold10b5-1 plan 2 parts	337,248	$20.21 average	$6.82M	7.4%	Form 4
Apr 15 – 16	Dirk Kersten Director	Sold10b5-1 plan 3 parts	99,613	$20.35 average	$2.03M	2.1%	Form 4
Apr 1	Erick Lucera Chief Financial Officer	Sold10b5-1 plan	5,727	$18.64	107K	4.4%	Form 4
Mar 30	Brian S Posner Director	Bought	2,000	$17.08	34K	15%	Form 4
Mar 11	Brian S Posner Director	Bought	2,000	$19.35	39K	17%	Form 4
Mar 11	Dirk Kersten Director	Sold10b5-1 plan	129,672	$19.52	$2.53M	2.7%	Form 4
Mar 9 – 10	Dirk Kersten Director	Sold10b5-1 plan 4 parts	688,788	$19.09 average	$13.2M	13%	Form 4
Mar 6	Brian S Posner Director	Bought	3,000	$15.06	45K	35%	Form 4

Oct 2
Brian S Posner
Director · bought 2,500 at $16.00
40K
10% of stake
Sep 4 – 810b5-1 plan
Johanna Friedl-Naderer
Chief Commercial Officer · sold 1,085 at avg $23.42
25K
0.7% of stake
Sep 4 – 810b5-1 plan
Douglas Kerr
Chief Medical Officer · sold 5,035 at avg $22.95
116K
3.0% of stake
Sep 810b5-1 plan
John Cox
CEO & President · sold 5,658 at $18.88
107K
1.3% of stake
Aug 13 – 1410b5-1 plan
Jason P Rhodes
Director · sold 2,586,928 at avg $25.20
$65.2M
86% of stake
Aug 1310b5-1 plan
Johanna Friedl-Naderer
Chief Commercial Officer · sold 226 at $26.28
6K
0.1% of stake
Aug 1310b5-1 plan
Douglas Kerr
Chief Medical Officer · sold 1,556 at $26.28
41K
0.9% of stake
Aug 1310b5-1 plan
Erick Lucera
Chief Financial Officer · sold 1,797 at $26.28
47K
1.5% of stake
Aug 1310b5-1 plan
John Cox
CEO & President · sold 4,986 at $26.28
131K
1.1% of stake
Jul 2710b5-1 plan
Dirk Kersten
Director · sold 261,460 at avg $25.51
$6.67M
6.8% of stake
Jul 6 – 710b5-1 plan
Jason P Rhodes
Director · sold 777,451 at avg $22.97
$17.9M
100% of stake
Jun 26 – 2910b5-1 plan
Jason P Rhodes
Director · sold 504,695 at avg $21.23
$10.7M
34% of stake
Jun 23 – 2510b5-1 plan
Jason P Rhodes
Director · sold 267,760 at avg $21.09
$5.65M
20% of stake
Jun 25No plan
Erick Lucera
Chief Financial Officer · sold 2,362 at $20.37
48K
1.9% of stake
Jun 22 – 2310b5-1 plan
Dirk Kersten
Director · sold 263,962 at avg $20.70
$5.46M
6.4% of stake
Jun 17 – 1810b5-1 plan
Dirk Kersten
Director · sold 84,355 at avg $20.10
$1.7M
2.0% of stake
Jun 1610b5-1 plan
Johanna Friedl-Naderer
Chief Commercial Officer · sold 145 at $18.33
3K
<0.1% of stake
Jun 1610b5-1 plan
Douglas Kerr
Chief Medical Officer · sold 887 at $18.33
16K
0.5% of stake
Jun 1610b5-1 plan
John Cox
CEO & President · sold 2,683 at $18.33
49K
0.6% of stake
Jun 8
Brian S Posner
Director · bought 2,000 at $16.94
34K
8.9% of stake
Jun 3
Brian S Posner
Director · bought 2,500 at $17.48
44K
13% of stake
May 26
Brian S Posner
Director · bought 2,000 at $18.21
36K
11% of stake
May 20
Brian S Posner
Director · bought 2,500 at $17.12
43K
16% of stake
May 1310b5-1 plan
Johanna Friedl-Naderer
Chief Commercial Officer · sold 228 at $18.36
4K
0.1% of stake
May 1310b5-1 plan
Douglas Kerr
Chief Medical Officer · sold 1,564 at $18.36
29K
0.9% of stake
May 1310b5-1 plan
Erick Lucera
Chief Financial Officer · sold 1,448 at $18.36
27K
1.2% of stake
May 1310b5-1 plan
John Cox
CEO & President · sold 3,311 at $18.36
61K
0.7% of stake
May 4 – 610b5-1 plan
Jason P Rhodes
Director · sold 106,723 at avg $18.14
$1.94M
8.6% of stake
Apr 2810b5-1 plan
Jason P Rhodes
Director · sold 227,337 at avg $18.38
$4.18M
16% of stake
Apr 23 – 2710b5-1 plan
Jason P Rhodes
Director · sold 384,549 at avg $18.47
$7.1M
24% of stake
Apr 21 – 2210b5-1 plan
Dirk Kersten
Director · sold 10,952 at avg $20.01
219K
0.3% of stake
Apr 20 – 2210b5-1 plan
Jason P Rhodes
Director · sold 834,302 at avg $19.75
$16.5M
39% of stake
Apr 17 – 2010b5-1 plan
Dirk Kersten
Director · sold 337,248 at avg $20.21
$6.82M
7.4% of stake
Apr 15 – 1610b5-1 plan
Dirk Kersten
Director · sold 99,613 at avg $20.35
$2.03M
2.1% of stake
Apr 110b5-1 plan
Erick Lucera
Chief Financial Officer · sold 5,727 at $18.64
107K
4.4% of stake
Mar 30
Brian S Posner
Director · bought 2,000 at $17.08
34K
15% of stake
Mar 11
Brian S Posner
Director · bought 2,000 at $19.35
39K
17% of stake
Mar 1110b5-1 plan
Dirk Kersten
Director · sold 129,672 at $19.52
$2.53M
2.7% of stake
Mar 9 – 1010b5-1 plan
Dirk Kersten
Director · sold 688,788 at avg $19.09
$13.2M
13% of stake
Mar 6
Brian S Posner
Director · bought 3,000 at $15.06
45K
35% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch DYN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with DYN

CompareIntrinsic value

VKTXViking Therapeutics Inc.

$26.45+1.36%10

AMRNAmarin Corp PLC\Uk

$12.25+1.66%46

ALKSAlkermes plc

$45.90+0.46%36

ABTAbbott Laboratories

$115.55+5.62%25

KNSAKiniksa Pharmaceuticals International, plc

$96.12+3.03%71

MNKDMannKind Corporation

$3.93+5.36%30

GOVXGeovax Labs Inc.

$0.17+2.44%35

OPKOpko Health Inc.

$1.77+2.91%25

Held by ETFs

DYN is in 51 US ETFs. The largest of them, with DYN's weight in each:

Spot a number that looks wrong? Check it in DYN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing DYN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.